Trevi Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2011-01-01

Employees: 25

Market Cap: $211.2M

Website: http://www.trevitherapeutics.com

Introduction: Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

Clinical Trials

Refractory Chronic Cough Improvement Via NAL ER (RIVER)

Phase 2

Completed

Conditions: Refractory Chronic Cough

Interventions: Drug: NAL ER
Drug: Placebo

First Posted Date: 2023-07-27

Last Posted Date: 2025-03-14

Lead Sponsor: Trevi Therapeutics

Target Recruit Count: 66

Registration Number: NCT05962151

Locations: 🇬🇧
Egin Research Ltd, High Wycombe, United Kingdom
🇬🇧
North Tyneside General Hospital - Northumbria Healthcare NHS Foundation Trust, North Shields, Tynemouth, United Kingdom
🇨🇦
McMaster University Medical Centre, Hamilton, Ontario, Canada

and more 11 locations

Cough Reduction in IPF with Nalbuphine ER

Phase 2

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: nalbuphine ER 27 mg
Drug: nalbuphine ER 54 mg
Drug: nalbuphine ER 108 mg
Drug: Placebo

First Posted Date: 2023-07-27

Last Posted Date: 2025-01-24

Lead Sponsor: Trevi Therapeutics

Target Recruit Count: 160

Registration Number: NCT05964335

Locations: 🇮🇹
Azienda Ospedaliera San Gerardo di Monza, Monza, Italy
🇳🇱
Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands
🇮🇹
Azienda Ospedaliera di Padova, Padua, Italy

and more 56 locations

A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough

Phase 2

Completed

Conditions: Idiopathic Pulmonary Fibrosis
Cough
Nalbuphine

Interventions: Drug: NAL ER
Drug: Placebo

First Posted Date: 2019-07-23

Last Posted Date: 2023-05-25

Lead Sponsor: Trevi Therapeutics

Target Recruit Count: 42

Registration Number: NCT04030026

Locations: 🇬🇧
02, Manchester, United Kingdom
🇬🇧
09, Cambridge, United Kingdom
🇬🇧
03, Southampton, United Kingdom

and more 12 locations

Nalbuphine ER Effects of Liver Disease on Pharmacokinetics and Itch

Phase 1

Conditions: Nalbuphine
Hepatic Impairment

Interventions: Drug: Nalbuphine ER -
Drug: Nalbuphine ER

First Posted Date: 2019-07-15

Last Posted Date: 2020-10-06

Lead Sponsor: Trevi Therapeutics

Target Recruit Count: 56

Registration Number: NCT04020016

Locations: 🇺🇸
01, Miami, Florida, United States
🇺🇸
02, Miami, Florida, United States
🇺🇸
03, Orlando, Florida, United States

Oral Abuse Potential Study of Nalbuphine

Phase 1

Completed

Conditions: Nalbuphine
Opioid Abuse

Interventions: Drug: Nalbuphine HCl solution
Drug: Placebo solution

First Posted Date: 2019-07-12

Last Posted Date: 2025-05-21

Lead Sponsor: Trevi Therapeutics

Target Recruit Count: 56

Registration Number: NCT04018664

Locations: 🇨🇦
001, Toronto, Ontario, Canada

PRISM Study-Pruritus Relief Through Itch Scratch Modulation

Phase 2

Completed

Conditions: Prurigo Nodularis

Interventions: Drug: Nalbuphine ER Tablets
Other: Matching Placebo Tablets

First Posted Date: 2018-04-13

Last Posted Date: 2023-05-06

Lead Sponsor: Trevi Therapeutics

Target Recruit Count: 353

Registration Number: NCT03497975

Locations: 🇩🇪
Study Site 208, Berlin, Germany
🇩🇪
Study Site 221, Düsseldorf, Germany
🇩🇪
Study Site 212, Heidelberg, Germany

and more 67 locations

Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

Phase 1

Completed

Conditions: Uremic Pruritus

Interventions: Drug: Nalbuphine HCL ER

First Posted Date: 2015-02-26

Last Posted Date: 2025-05-22

Lead Sponsor: Trevi Therapeutics

Target Recruit Count: 22

Registration Number: NCT02373215

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Phase 2

Completed

Conditions: Pruritus
Prurigo Nodularis
Nodularis Prurigo
Prurigo

Interventions: Drug: nalbuphine HCl ER tablets 90 mg BID
Drug: nalbuphine HCl ER tablets 180 mg BID
Drug: Placebo tablets BID

First Posted Date: 2014-06-25

Last Posted Date: 2025-05-21

Lead Sponsor: Trevi Therapeutics

Target Recruit Count: 62

Registration Number: NCT02174419

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇩🇪
University of Münster, Münster, Germany

and more 1 locations

Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

Phase 2

Completed

Conditions: Prurigo Nodularis
Nodularis Prurigo
Prurigo

Interventions: Drug: nalbuphine HCl ER

First Posted Date: 2014-06-25

Last Posted Date: 2025-05-21

Lead Sponsor: Trevi Therapeutics

Target Recruit Count: 36

Registration Number: NCT02174432

Locations: 🇩🇪
University of Münster, Münster, Germany

Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

Phase 2

Completed

Conditions: Uremic Pruritus
Pruritus

Interventions: Drug: nalbuphine HCl ER tablets 60 mg BID
Drug: nalbuphine HCl ER tablets 120mg BID
Drug: Placebo tablets BID

First Posted Date: 2014-05-21

Last Posted Date: 2025-05-21

Lead Sponsor: Trevi Therapeutics

Target Recruit Count: 373

Registration Number: NCT02143648

Locations: 🇺🇸
North America Research Institute, Azusa, California, United States
🇺🇸
Southwest Renal Research Institute, Chattanooga, Tennessee, United States
🇺🇸
Fresenius Medical Care of Evergreen Park, Evergreen Park, Illinois, United States

and more 42 locations

Home Terms & Conditions Privacy Policy